KCM
LPCN icon

Knoll Capital Management’s Lipocine LPCN Stock Holding History

Knoll Capital Management’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2,941
Closed -$141K – 22
2019
Q3 		$141K Hold
2,941
– – 0.13% 22
2019
Q2 		$97K Hold
2,941
– – 0.08% 21
2019
Q1 		$116K Hold
2,941
– – 0.09% 17
2018
Q4 		$65K Hold
2,941
– – 0.07% 15
2018
Q3 		$69K Hold
2,941
– – 0.06% 17
2018
Q2 		$65K Buy
+2,941
New +$70.1K 0.06% 17
2017
Q4 		– Sell
-1,471
Closed -$99K – 14
2017
Q3 		$99K Hold
1,471
– – 0.08% 16
2017
Q2 		$101K Buy
+1,471
New +$96K 0.13% 15

Other funds holding LPCN

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return
CL
Choreo LLC Rockford, Illinois $8.15B AUM 20.12% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Knoll Capital Management's LPCN Position: Q4 2019 in Review

Knoll Capital Management sold out of Lipocine (LPCN) in Q4 2019, closing a stake of 2,941 shares — an estimated $141K sold.

Knoll Capital Management first reported a position in LPCN in Q2 2017 and held it in 8 quarters. The position peaked at $141K in Q3 2019. 32 funds tracked by Wall St. Rank hold LPCN as of Q4 2019.

  • Knoll Capital Management reported no remaining Lipocine position as of Q4 2019 after selling out during the quarter.
  • Knoll Capital Management sold 2,941 Lipocine shares in Q4 2019, an estimated $141K.
  • Knoll Capital Management first reported a position in Lipocine in Q2 2017 and held it in 8 quarters.
  • Knoll Capital Management's Lipocine position peaked at $141K in Q3 2019.
  • 32 funds tracked by Wall St. Rank held Lipocine as of Q4 2019.

Based on Knoll Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.